Severe cutaneous adverse drug reaction in intensive care

Authors

  • Antoine Gaillet 1. Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique – Hôpitaux de Paris (AP-HP), Créteil, France. 2. Groupe de Recherche Clinique CARMAS, Université Paris-Est-Créteil (UPEC), Créteil, France. 3. Centre National de Référence des Dermatoses Bulleuses Toxiques, Hôpital Henri Mondor, Créteil
  • Saskia Ingen-Housz-Oro Francais1. Centre National de Référence des Dermatoses Bulleuses Toxiques, Hôpital Henri Mondor, Créteil. 2. Service de Dermatologie, Hôpitaux Universitaires Henri Mondor, Assistance Publique – Hôpitaux de Paris (AP-HP), Créteil, France 
  • Olivier Chosidow Service de Dermatologie, Hôpitaux Universitaires Henri Mondor, Assistance Publique – Hôpitaux de Paris (AP-HP), Créteil, France
  • Nicolas de Prost 1. Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique – Hôpitaux de Paris (AP-HP), Créteil, France. 2. Groupe de Recherche Clinique CARMAS, Université Paris-Est-Créteil (UPEC), Créteil, France. 3. Centre National de Référence des Dermatoses Bulleuses Toxiques, Hôpital Henri Mondor, Créteil https://orcid.org/0000-0002-4833-4320

DOI:

https://doi.org/10.37051/mir-00149

Keywords:

Severe cutaneous adverse drug reaction, epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), intensive care

Abstract

Severe cutaneous adverse drug reaction (epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP)) are complex situations, both in their diagnostic and therapeutic approach, justifying multidisciplinary management in a specialized center. In addition to mucocutaneous involvement, visceral complications can occur, which can be life-threatening in the short term. The initial management, essentially symptomatic, is intended to prevent possible long-term sequelae. Physicians should be aware of the potential role of high-risk drugs in triggering severe cutaneous adverse drug reaction, especially when predisposing factors are present. All severe cutaneous adverse drug reaction should be reported to pharmacovigilance. At a distance, allergological tests can help to confirm the culprit drug and to decide on possible alternatives.  

Author Biography

Olivier Chosidow, Service de Dermatologie, Hôpitaux Universitaires Henri Mondor, Assistance Publique – Hôpitaux de Paris (AP-HP), Créteil, France

Dermatology Department, Henri Mondor University Hospitals, Assistance Publique – Hôpitaux de Paris (AP-HP), Créteil, France 

MD, PhD

Image

Published

2023-04-06

How to Cite

Gaillet, A., Ingen-Housz-Oro, S., Chosidow, O., & de Prost, N. (2023). Severe cutaneous adverse drug reaction in intensive care. Médecine Intensive Réanimation, 32(2), 159–172. https://doi.org/10.37051/mir-00149

Most read articles by the same author(s)